Figure S3 from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Change from baseline in target lesion diameters: 3A, Spider plot of the change in the sum of target lesion diameters from baseline over time for evaluable immunotherapy naive patients (n=21). The lines are color coded based on best response; * pretracheal LN measured 8 mm at last scan resulting in a response of CR in the target lesion, but overall response of PR due to presence of non-target lesion. 3B, Spider plot of the change in the sum of target lesion diameters from baseline over time for evaluable immunotherapy failure patients (n=29). The lines are color coded based on best response.
Authors: Michael R. Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, Joseph T. Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Rachel E. Sanborn, Jonathan W. Goldman, Maurice Zauderer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361939343